148 related articles for article (PubMed ID: 10753831)
1. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
Schiffer CA; Miller K; Larson RA; Amrein PC; Antin JH; Zani VJ; Stone RM
Blood; 2000 Apr; 95(8):2530-5. PubMed ID: 10753831
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
Archimbaud E; Ottmann OG; Yin JA; Lechner K; Dombret H; Sanz MA; Heil G; Fenaux P; Brugger W; Barge A; O'Brien-Ewen C; Matcham J; Hoelzer D
Blood; 1999 Dec; 94(11):3694-701. PubMed ID: 10572081
[TBL] [Abstract][Full Text] [Related]
3. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
[TBL] [Abstract][Full Text] [Related]
4. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG
Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014
[TBL] [Abstract][Full Text] [Related]
5. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK
Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.
Goodnough LT; Kuter DJ; McCullough J; Slichter SJ; DiPersio J; Romo J; Peterson R; Smith KJ; Raife T; Tomita D; Armstrong S
Blood; 2001 Sep; 98(5):1346-51. PubMed ID: 11520781
[TBL] [Abstract][Full Text] [Related]
8. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B; Vredenburgh J; Overmoyer B; Gilbert C; Chap L; Menchaca DM; Cruickshank S; Glaspy J
Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin therapy increases platelet yields in healthy platelet donors.
Kuter DJ; Goodnough LT; Romo J; DiPersio J; Peterson R; Tomita D; Sheridan W; McCullough J
Blood; 2001 Sep; 98(5):1339-45. PubMed ID: 11520780
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.
Nakamura M; Toombs CF; Duarte IG; Ronson RS; Schmarkey LS; Katzmark SL; Robinson J; Dillehay DL; Vinten-Johansen J; Guyton RA
Ann Thorac Surg; 1998 Oct; 66(4):1216-23. PubMed ID: 9800809
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; McNiece IK
Blood; 1996 Jul; 88(1):366-76. PubMed ID: 8704197
[TBL] [Abstract][Full Text] [Related]
13. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
Moskowitz CH; Hamlin PA; Gabrilove J; Bertino JR; Portlock CS; Straus DJ; Gencarelli AN; Nimer SD; Zelenetz AD
Ann Oncol; 2007 Nov; 18(11):1842-50. PubMed ID: 17872903
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.
Basser RL; Underhill C; Davis I; Green MD; Cebon J; Zalcberg J; MacMillan J; Cohen B; Marty J; Fox RM; Begley CG
J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133
[TBL] [Abstract][Full Text] [Related]
15. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
16. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.
Nomura S; Dan K; Hotta T; Fujimura K; Ikeda Y
Blood; 2002 Jul; 100(2):728-30. PubMed ID: 12091377
[TBL] [Abstract][Full Text] [Related]
17. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
18. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
19. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
Harker LA; Marzec UM; Novembre F; Sundell IB; Waller EK; Karpatkin S; McClure HM; Kelly AB; Stead RB
Blood; 1998 Jun; 91(12):4427-33. PubMed ID: 9616135
[TBL] [Abstract][Full Text] [Related]
20. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.
O'Malley CJ; Rasko JE; Basser RL; McGrath KM; Cebon J; Grigg AP; Hopkins W; Cohen B; O'Byrne J; Green MD; Fox RM; Berndt MC; Begley CG
Blood; 1996 Nov; 88(9):3288-98. PubMed ID: 8896392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
